Transition from Syringe to Autoinjector Based on Bridging Pharmacokinetics and Pharmacodynamics of the P2Y12 Receptor Antagonist Selatogrel in Healthy Subjects
Sign Up to like & getrecommendations! Published in 2021 at "Clinical Pharmacokinetics"
DOI: 10.1007/s40262-021-01097-9
Abstract: Selatogrel is a potent, reversible, and selective antagonist of the platelet P2Y12 receptor currently developed for the treatment of acute myocardial infarction (AMI). In the completed Phase I/II studies, selatogrel was subcutaneously (s.c.) administered as… read more here.
Keywords: selatogrel; phase; formulation; treatment ... See more keywords
Insights from In Vitro and Clinical Data to Guide Transition from the Novel P2Y12 Antagonist Selatogrel to Clopidogrel, Prasugrel, and Ticagrelor.
Sign Up to like & getrecommendations! Published in 2021 at "Thrombosis and haemostasis"
DOI: 10.1055/s-0040-1721773
Abstract: Reduced pharmacodynamic (PD) effects of irreversible oral P2Y12 receptor antagonists have been reported when administered during cangrelor infusion. Therefore, the PD interaction liability of the novel P2Y12 receptor antagonist selatogrel with irreversible (i.e., clopidogrel, prasugrel)… read more here.
Keywords: ticagrelor; clopidogrel prasugrel; novel p2y12; selatogrel ... See more keywords